Leon Overview
- Founded
-
2010

- Status
-
Private
- Employees
-
17

- Latest Deal Type
-
2ndary - Private
- Investors
-
10
Leon General Information
Description
Developer of drugs through nanoscience designed to offer better patient outcomes. The company's drugs specialize in improving the bioavailability of poorly water-soluble medicine by using their proprietary technology to create either polymeric or crystalline nanoparticles, enabling medical professionals to get nano-formulated drugs with meaningful differentiation and added benefits.
Contact Information
Website
www.leon-nanodrugs.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
- Kopernikusstraße 9
- 81679 Munich
- Germany
+49 089 000000000
Leon Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Secondary Transaction - Private | 01-Jul-2020 | 000.00 | Completed | Generating Revenue | ||
2. Later Stage VC (Series B) | 16-Apr-2020 | 000.00 | Completed | Generating Revenue | ||
1. Early Stage VC (Series A) | 27-Jul-2015 | $20.5M | $20.5M | 0000 | Completed | Generating Revenue |
Leon Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Developer of drugs through nanoscience designed to offer better patient outcomes. The company's drugs specialize in impr
Drug Discovery
Munich, Germany
17
As of 2022
000.00
00000000000
000.00
Leon Competitors (15)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Scynexis | Formerly VC-backed | Jersey City, NJ | 00 | 00000 | 00000000 | 00000 |
0000000 0000000000 | Corporate Backed or Acquired | Waltham, MA | 00 | 00000 | 000000&0 | 00000 |
000000000 | Corporate Backed or Acquired | Saint-Julien- en-Genevois, France | 00 | 000.00 | 000000&0 | 000.00 |
000000 00000000000 | Corporate Backed or Acquired | Richmond, CA | 000000000 - | |||
000000000 00000000 | Formerly VC-backed | Vancouver, Canada | 000 | 000.00 | 000000&0 | 000.00 |
Leon Patents
Leon Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
EP-4008322-A1 | Nanometer sized lecithin particles for parenteral administration | Pending | 25-May-2020 | 0000000000 | 0 |
EP-3915546-A1 | Use of acid as solvent for precipitations | Pending | 25-May-2020 | 0000000000 | 0 |
EP-3915544-A1 | Method for producing a liposome dispersion | Inactive | 25-May-2020 | 0000000000 | 0 |
EP-3915673-A1 | Method for checking the operability of a system for the production of nanoparticles by selective precipitation from supersaturated solutions | Inactive | 25-May-2020 | 000000000 | 0 |
CA-3139380-A1 | Method for producing nanoparticles | Pending | 16-May-2019 | A61K9/5123 |
Leon Executive Team (9)
Leon Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Cornelia Beier | Leon | Co-Founder & Board Member | 000 0000 |
Enno Spillner | Evotec | Supervisory Board Member | 000 0000 |
Frank Mathias Ph.D | Self | Supervisory Board Member | 000 0000 |
Gerhard Ries Ph.D | LifeCare Partners | Supervisory Board Member | 000 0000 |
Hubert Birner Ph.D | TVM Capital Life Science | Chairman of the Supervisory Board | 000 0000 |
Leon Signals
Leon Investors (10)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
BayBG Bayerische Beteiligungsgesellschaft | PE/Buyout | Minority | 000 0000 | 000000 0 | |
BayBG Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Eckenstein-Geigy-Stiftung | Not-For-Profit Venture Capital | Minority | 000 0000 | 000000 0 | |
Evotec | Corporation | Minority | 000 0000 | 000000 0 | |
Albany Private Equity Holding | Angel (individual) | Minority | 000 0000 | 000000 0 |